Stryker unit charged in marketing scheme: DOJ
Stryker Biotech LLC and top management have been indicted on charges they engaged in a fraudulent marketing scheme for certain medical devices, the U.S. Justice Department said on Wednesday.
Stryker Biotech, based in Hopkinton, Massachusetts, is a division of Stryker Corp
The indictment charged Stryker Biotech, its former president, Mark Philip, and three current sales managers with a scheme that involved devices used during invasive spinal and long bone surgeries.
Philip and the company were also charged with making false statements to the U.S. Food and Drug Administration.
Stryker and its executives promoted devices known as OP-1 Implant and OP-1 Putty for use in a manner that was different from the use approved by the FDA, authorities said.
(Editing by Steve Orlofsky)
© Copyright Thomson Reuters 2024. All rights reserved.